Focused chemical genetic screen reveals sensitivity of FLT3-mutant AML cell lines to several FDA-approved compounds. (A) Heat map shows treatment response of FLT3-ITD (MOLM-14 and MV4-11) or FLT3 wild-type (WT) (THP-1, ML-2, KU812, and K562) leukemic cells. Viability measurements were conducted by the CellTiterGlo (CTG) Viability Assay. For full data set, see supplemental Figure 1A. Blue, sensitivity; red, resistance. (B) Significance of viability difference between FLT3 WT and ITD⁺ cells upon drug exposure. (C) Dose-response curve of ITD⁺ (red) or control (black) leukemic cells with CDK4/6 inhibitor palbociclib. Cells were incubated with increasing concentrations for 72 hours. Cell viability and proliferation were assessed by using the CTG assay. IC₅₀ values were calculated by using GraphPad Prism software. Error bars indicate ± SEM.